Literature DB >> 19963407

Renal cell carcinoma with caval involvement: contemporary strategies of surgical treatment.

Francesca Manassero1, Andrea Mogorovich, Giuseppe Di Paola, Francesca Valent, Vittorio Perrone, Stefano Signori, Ugo Boggi, Cesare Selli.   

Abstract

OBJECTIVES: We retrospectively evaluated the outcome of the surgical treatment of patients with renal cell carcinoma (RCC) and extensive inferior vena cava (IVC) involvement. Our aim was to investigate if a particular surgical technique could reduce morbidity and complications associated with this condition.
MATERIALS AND METHODS: From 1996 to 2007, 22 patients with RCC and extensive IVC involvement underwent radical surgical treatment with the intention to avoid, whenever possible, sternotomy and cardiopulmonary bypass. The level of the tumor thrombus was I (<2 cm above the renal vein) in 2 patients, II (below the intrahepatic vena cava) in 9 patients, III (intrahepatic vena cava below the diaphragm) in 7 patients, and IV (atrial) in 4 patients. Extracorporeal vascular bypass was used for 4 patients with level IV and for 2 patients with level III tumor thrombi, with hypothermic circulatory arrest in 2 patients. Extensive liver mobilization techniques were adopted in 16 patients. Overall and cancer-specific survival (CSS) were analyzed based on tumor extent (N0M0, N+M+), pathologic stage (pT3b, pT3c, pT4), thrombus level, and caval wall infiltration.
RESULTS: Two patients died within 1 month of surgery and the remaining 20 patients have a mean follow-up of 32.2 months (range 6-90): 8 are alive (overall survival 40%), but 2 with disease (CSS 30%). A total of 10 severe complications developed in 8 patients (36%). Both overall and CSS were significantly associated with tumor stage (Log-rank P = 0.0237 and 0.0465), presence of nodal or systemic metastases (Log-rank P = 0.0835 and 0.0669; Wilcoxon's test P = 0.0407 and 0.0411), and caval wall infiltration (Log-rank P = 0.0200 and 0.0418).
CONCLUSIONS: Despite the low overall survival, related to the high percentage of nodal and systemic metastases, aggressive surgical management with resection of synchronous metastatic disease for symptom palliation and cytoreduction, followed by immunotherapy is justified in this setting. A transabdominal approach to RCC and IVC involvement, even in patients with level III thrombus, can provide the surgeon with an exposure similar to thoracoabdominal incisions without the complications associated with thoracotomy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19963407     DOI: 10.1016/j.urolonc.2009.09.018

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  10 in total

1.  Surgical resection of recurrent inferior vena cava tumor following radical nephrectomy for renal cell carcinoma: A case report.

Authors:  Guangyuan Li; Zhiqiang Zhang; Dongdong Xie; Nan Ye; Dexin Yu
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

2.  Preoperative Prediction of Inferior Vena Cava Wall Invasion of Tumor Thrombus in Renal Cell Carcinoma: Radiomics Models Based on Magnetic Resonance Imaging.

Authors:  Zhaonan Sun; Yingpu Cui; Chunru Xu; Yanfei Yu; Chao Han; Xiang Liu; Zhiyong Lin; Xiangpeng Wang; Changxin Li; Xiaodong Zhang; Xiaoying Wang
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

Review 3.  Surgical treatment of renal cell carcinoma with inferior vena cava tumor thrombus.

Authors:  Shi-Min Yuan
Journal:  Surg Today       Date:  2022-01-03       Impact factor: 2.540

4.  Determinants of outcomes after resection of renal cell carcinoma with venous involvement.

Authors:  Abhinav Sidana; Jatinder Goyal; Piyush Aggarwal; Payal Verma; Ronald Rodriguez
Journal:  Int Urol Nephrol       Date:  2012-10-20       Impact factor: 2.370

5.  Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy.

Authors:  Ross M Simon; Timothy Kim; Patrick Espiritu; Tony Kurian; Wade J Sexton; Julio M Pow-Sang; Einar Sverrisson; Philippe E Spiess
Journal:  Int Braz J Urol       Date:  2015 Sep-Oct       Impact factor: 1.541

6.  Technical Intraoperative Maneuvers for the Management of Inferior Vena Cava Thrombus in Renal Cell Carcinoma.

Authors:  Dionysios Dellaportas; Nikolaos Arkadopoulos; Ioannis Tzanoglou; Evgenios Bairamidis; George Gemenetzis; Pantelis Xanthakos; Constantinos Nastos; Georgia Kostopanagiotou; Ioannis Vassiliou; Vassilios Smyrniotis
Journal:  Front Surg       Date:  2017-09-06

7.  Splenomesenteric bypass as revascularisation technique after iatrogenic injury of the superior mesenteric artery during radical nephrectomy: A case report.

Authors:  Catarina Afonso; Jorge Pereira; Pedro Eufrásio; Júlio Constantino; Paulo Rebelo
Journal:  Int J Surg Case Rep       Date:  2019-05-30

8.  Less invasive treatment option for renal carcinoma with venous tumor thrombus.

Authors:  Zoltán Nagy; József Pánovics; Attila Szendrői; Attila M Szász; László Harsányi; Imre Romics
Journal:  Croat Med J       Date:  2014-06-01       Impact factor: 1.351

9.  Renal cell carcinoma with venous extension: prediction of inferior vena cava wall invasion by MRI.

Authors:  Lisa C Adams; Bernhard Ralla; Yi-Na Y Bender; Keno Bressem; Bernd Hamm; Jonas Busch; Florian Fuller; Marcus R Makowski
Journal:  Cancer Imaging       Date:  2018-05-03       Impact factor: 3.909

Review 10.  Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery.

Authors:  Stênio de Cássio Zequi; Walter Henriques da Costa; Fernando Korkes; Rodolfo Borges Dos Reis; Wilson Francisco Schreiner Busato; Wagner Eduardo Matheus; Deusdedit Cortez Vieira da Silva Neto; Felipe de Almeida E Paula; Gustavo Franco Carvalhal; Lucas Nogueira; Roni de Carvalho Fernandes; Adriano Gonçalves E Silva; André Deeke Sasse; André P Fay; Denis Leonardo Jardim; Diogo Assed Bastos; Diogo Augusto Rodrigues da Rosa; Evanius Wierman; Fabio Kater; Fabio A Schutz; Fernando Cotait Maluf; Fernando Nunes Galvão de Oliveira; Igor Alexandre Protzner Morbeck; José Augusto Rinck; Karine Martins da Trindade; Manuel Caitano Maia; Vinicius Carrera Souza; Fernando Sabino Marques Monteiro; Andrey Soares
Journal:  Ther Adv Urol       Date:  2019-09-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.